MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
-0.180
-5.57%
After Hours: 3.020 -0.03 -0.98% 17:33 07/15 EDT
OPEN
3.270
PREV CLOSE
3.230
HIGH
3.600
LOW
2.690
VOLUME
760.59K
TURNOVER
--
52 WEEK HIGH
3.600
52 WEEK LOW
1.039
MARKET CAP
70.25M
P/E (TTM)
-1.2172
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONCS stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.

EPS

ONCS News

More
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 13h ago
55 Biggest Movers From Yesterday
Gainers Perceptron, Inc. (NASDAQ: PRCP) shares jumped 107% to close at $6.50 on Tuesday after the company received an order from an automotive supplier for its in-line measurement technology.
Benzinga · 15h ago
OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced the promising potential of its novel DNA–encodable vaccine candidate, CORVax12, which is des
PR Newswire · 2d ago
OncoSec to be Featured in "Grand Rounds: a Webinar in Biotech and Specialty Pharma," Webinar Hosted by Alliance Global Partners
PR Newswire · 6d ago
OncoSec Set to Join Russel Microcap® Index
PR Newswire · 06/24 14:00
OncoSec Reports Will Join Russell Microcap Index Jun. 29
Benzinga · 06/24 13:29
OncoSec Medical Highlights 2 Late-Breaking Abstracts On TAVO-PLUS At AACR Meeting
OncoSec Medical Incorporated (the "Company" or "OncoSec") (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power
Benzinga · 06/22 13:24
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12 (IL-12) plasmid
PR Newswire · 06/22 13:05

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About ONCS

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).
More

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.